Trademarkia Logo

Canada

C$
Trademark Search in Canada
VISLUCI

View On IC.GC.CA

VISLUCI
ADVERTISED

on 9 Apr 2025

Last Applicant/ Owned by

Blaze Bioscience, Inc.

530 Fairview Avenue North,Suite 1400Seattle WA 98109

US

Serial Number

2208488 filed on 1st Aug 2022

Correspondent Address

GOWLING WLG (CANADA) LLP

SUITE 2600, 160 ELGIN STREETOTTAWA

ONTARIO

CA

K1P1C3

VISLUCI

Trademark usage description

diagnostic, imaging, and therapeutic agents, preparations and substances, namely, diagnostic biomarker reagents for detecting, diagnosing, monitoring, Read More

Classification Information

Class [005]
Diagnostic, imaging, and therapeutic agents, preparations and substances, namely, diagnostic biomarker reagents for detecting, diagnosing, monitoring, and treating diseases, disorders and conditions, namely cancer, oncological diseases and disorders, brain and central nervous system diseases and disorders, skin and epithelial diseases and disorders, benign growths, metastatic disease, vascular lesions, blood diseases and disorders, vasculature diseases and disorders, and the foregoing in in situ, ex vivo and pathology samples; medical diagnostic biomarker reagents; diagnostic biomarker reagents for medical purposes; imaging and detection agents, namely, diagnostic biomarker reagents, for diagnosing and monitoring cancer, oncological diseases and disorders, brain and central nervous system diseases and disorders, skin and epithelial diseases and disorders, benign growths, metastatic disease, vascular lesions, blood diseases and disorders, vasculature diseases and disorders, and the foregoing in in situ, ex vivo and pathology samples; none of the foregoing for detecting, diagnosing, or treating diseases originating in the eye, with the exception of melanoma, or for detecting, diagnosing, or treating angiogenesis.

Classification kind code

11

Class [042]
Medical research in the field of cancer, oncological diseases and disorders, brain and central nervous system diseases and disorders, skin and epithelial diseases and disorders, benign growths, metastatic disease, vascular lesions, blood diseases and disorders, vasculature diseases and disorders; scientific research for medical purposes in the field of cancer, oncological diseases and disorders, brain and central nervous system diseases and disorders, skin and epithelial diseases and disorders, benign growths, metastatic disease, vascular lesions, blood diseases and disorders, vasculature diseases and disorders; product research and development for medical purposes in the field of cancer, oncological diseases and disorders, brain and central nervous system diseases and disorders, skin and epithelial diseases and disorders, benign growths, metastatic disease, vascular lesions, blood diseases and disorders, vasculature diseases and disorders; product development in the field of the detection, location, and treatment of cancer, oncological diseases and disorders, brain and central nervous system diseases and disorders, skin and epithelial diseases and disorders, benign growths, metastatic disease, vascular lesions, blood diseases and disorders, vasculature diseases and disorders; design and development of therapies, diagnostic agents, imaging agents, and medical devices for detecting, locating, and treating cancer, oncological diseases and disorders, brain and central nervous system diseases and disorders, skin and epithelial diseases and disorders, benign growths, metastatic disease, vascular lesions, blood diseases and disorders, vasculature diseases and disorders, all in the field of diagnostic biomarker reagents; none of the foregoing for detecting, diagnosing, or treating diseases originating in the eye, with the exception of melanoma, or for detecting, diagnosing, or treating angiogenesis.

Classification kind code

11

Mark Details

Serial Number

2208488

Mark Type

Trademark

Legal History

Show more

Action TakenStatus
Submitted for opposition 22
on 27th Oct 2023		Search Recorded
Submitted for opposition 130
on 28th Sept 2023		Note to file
Submitted for opposition 256
on 10th Jul 2023		Notification of Possible Opposition Sent
Submitted for opposition 231
on 20th Apr 2023		Limitation
Submitted for opposition 48
on 14th Mar 2023		Agent Changed
Submitted for opposition 257
on 8th Sept 2022		Designation Notification - Madrid Protocol
Submitted for opposition 31
on 7th Sept 2022		Formalized
Submitted for opposition 1
on 7th Sept 2022		Created
Submitted for opposition 228
on 1st Aug 2022		International Registration
Submitted for opposition 30
on 1st Aug 2022		Filed